NCT05980767 Short Duration Electrical Stimulation to Improve Outcomes After Cubital Tunnel Release (SELECT) Trial
| NCT ID | NCT05980767 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Epineuron Technologies Inc. |
| Condition | Neuropathy;Peripheral |
| Study Type | INTERVENTIONAL |
| Enrollment | 26 participants |
| Start Date | 2023-11-01 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 26 participants in total. It began in 2023-11-01 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A novel temporary peripheral nerve stimulation system that delivers electrical stimulation therapy in a cubital tunnel release model will be evaluated for feasibility.
Eligibility Criteria
Inclusion Criteria: * Ulnar neuropathy at the elbow Exclusion Criteria: * Peripheral neuropathy outside of nerve of interest * Patients with any active implanted device
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05980767 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Neuropathy;Peripheral. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05980767 currently recruiting?
Yes, NCT05980767 is actively recruiting participants. Contact the research team at clinops@epineurontech.com for enrollment information.
Where is the NCT05980767 trial being conducted?
This trial is being conducted at Hamilton, Canada, Hamilton, Canada.
Who is sponsoring the NCT05980767 clinical trial?
NCT05980767 is sponsored by Epineuron Technologies Inc.. The trial plans to enroll 26 participants.